Prevalence of Incretin-Mimetic and Sodium-Glucose-Transporter-2-Inhibitor Therapy in German Hospitalized Type-2 Diabetics Following Myocardial Revascularization: An Observational Study

INTRODUCTION: Real-world data indicate that sodium glucose transporter-2–inhibitor therapy and/or incretin mimetics are not widely prescribed in type-2 diabetics with atherosclerotic vascular disease. We hypothesized that incretin-mimetic therapy is associated with better overall survival and 1-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Pliquett, Rainer U., Golle, Linda, Wienke, Andreas, Girndt, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843777/
https://www.ncbi.nlm.nih.gov/pubmed/33196958
http://dx.doi.org/10.1007/s13300-020-00956-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843777/
https://www.ncbi.nlm.nih.gov/pubmed/33196958
http://dx.doi.org/10.1007/s13300-020-00956-1

Ejemplares similares